JNJ Finance Insights

0s—5m

Sam Stovall indicates that technology comprises 40% of the S&P 500, highlighting a tech-driven market.

Stovall notes that technology stocks are currently trading at a discount compared to their earnings over the past five, ten, and twenty years relative to the S&P 500.

Historically, October is the best month of midterm election years, with November following as the second best month.

Stovall suggests that a sharp rally in defensive sectors may signal investor concerns about potential negative market developments.

He emphasizes that when the market rises in the third quarter of a midterm election year, investors should maintain positions in winning sectors like healthcare, energy, and technology.

Our interpretation: The current shift towards defensive sectors such as healthcare and consumer staples, combined with a tech sector trading at historical discounts, indicates that while there are concerns about market stability, historical trends during midterm election years may support equity performance, particularly if earnings expectations remain robust.

JNJ / Reason

Johnson & Johnson is part of the healthcare sector, which is highlighted as a strong performer.

JNJ / Transmission

The commentary on healthcare's resilience suggests it may continue to attract investment. This can support JNJ's stock performance.

5m—10m

Technology is projected to experience strong earnings growth, with expectations of double-digit increases through 2027 and a potential rise of over 30% in that year.

Healthcare is anticipated to outperform the market during midterm election years, bolstered by historical trends and expected earnings improvements.

Industrials are identified as a sector with potential for growth due to increased spending in industrial activities, despite concerns about transportation costs driven by higher energy prices.

Historically, maintaining positions in the best-performing sectors from midterm election years through the following year has resulted in an average price change of 16%.

Consumer staples are regarded positively from a defensive standpoint, although rising tariffs and costs are impacting profit margins.

Our interpretation: The current focus on sectors like technology, healthcare, and industrials, alongside the defensive positioning in consumer staples, suggests that while there are concerns about market stability, historical patterns during midterm election years may support continued equity performance if earnings expectations remain strong.

JNJ / Reason

Johnson & Johnson is a significant company in the healthcare sector, which is expected to outperform.

JNJ / Transmission

The anticipated outperformance of healthcare during midterm election years highlights JNJ's potential for growth. This can enhance investor confidence in JNJ's stock performance.

15m—20m

The current bull market is noted as the most expensive among those that have celebrated their fourth birthday since World War II.

The S&P 500 began 2026 with a PE ratio of 23.3, which has improved to below 20 due to faster-than-expected earnings growth.

Any normal market correction may be deferred to 2027 if earnings continue to grow at an accelerated pace.

Investors are advised to be selective, as opportunities remain across all 11 sectors.

Healthcare is highlighted as a top investment opportunity, with an estimated growth of 22% compared to 16.8% for the S&P 500.

High debt levels, including government and retail margin debt, could threaten the bull market if the 10-year yield rises significantly.

Our interpretation: The combination of improving earnings and selective investment strategies may provide resilience in the equity markets, despite potential risks from rising debt levels and interest rates.

JNJ / Reason

Johnson & Johnson is a key player in the healthcare sector, which is emphasized as a top investment opportunity.

JNJ / Transmission

The focus on healthcare growth may attract investment into healthcare stocks. This can positively impact Johnson & Johnson through enhanced investor sentiment.

10m—15m

Lincoln National offers a dividend yield of 4.5%, which is viewed as impressive.

As interest rates rise steadily, Lincoln National's margins and profits are expected to improve.

Financial stocks generally perform better in rising interest rate environments, indicating a favorable buying opportunity in the current market.

Healthcare is considered relatively recession-proof, as demand for medicine persists regardless of economic conditions.

Abby, a bio-pharma giant, has transitioned from being an unloved company to gaining more acceptance in the market.

Our interpretation: The current market conditions suggest that investors may benefit from focusing on financial and healthcare stocks, particularly as interest rates rise and demand for essential services remains stable.

JNJ / Reason

Healthcare is discussed as relatively recession-proof, indicating stability.

JNJ / Transmission

The commentary suggests that demand for healthcare persists regardless of economic conditions. This can support Johnson & Johnson's stock performance as it remains resilient in volatile markets.

0s—5m

Glenn Smith notes that historical trends indicate the stock market typically rises by an average of 15 percent in the 12 months following midterm elections.

He emphasizes that while earnings are crucial, forward guidance from companies is becoming increasingly important as expectations rise.

Smith warns against overconcentration in AI and tech stocks, highlighting that companies like CoreWeave are struggling due to high debt levels in a rising interest rate environment.

CoreWeave's debt of $35 billion could pose significant risks if interest rates continue to increase.

Glenn expresses confidence in companies like Nvidia, Broadcom, and Lam Research, suggesting they will perform well despite market volatility.

Our interpretation: The reliance on debt among certain tech firms may lead to increased volatility and risk, particularly if interest rates rise, prompting investors to reassess their exposure to high-debt companies.

JNJ / Reason

Johnson & Johnson is also mentioned in the context of favored healthcare stocks.

JNJ / Transmission

The discussion includes J&J as a solid investment in healthcare. This can enhance JNJ's attractiveness to investors.

5m—10m

Glenn Smith highlights a preference for healthcare and financial sectors, citing JP Morgan's strong net interest margins as a key factor for potential success if rates remain stable.

He expects both Johnson & Johnson and UnitedHealth to perform well in the current market environment, even amidst a potential secular bear market.

Smith warns against overconcentration in technology stocks, advising investors to consider reducing positions in high-performing assets like Micron and Nvidia if they represent a large portion of their portfolios.

While favoring major AI companies such as Nvidia, Broadcom, and Lam Research, he emphasizes that investment strategies should be tailored to individual investor circumstances.

The most likely scenario for December is no rate hike or cut, which influences their current investment strategy.

Our interpretation: If inflation decreases and the Fed maintains rates, sectors like healthcare and financials may benefit, while high expectations in tech could lead to volatility if earnings guidance disappoints, impacting investor sentiment and portfolio allocations.

JNJ / Reason

Johnson & Johnson is mentioned as a favorable investment in healthcare.

JNJ / Transmission

Expectations for Johnson & Johnson's performance are positive in the current market. This can drive demand for its stock among investors.

0s—5m

Wells Fargo reported mixed results with earnings of $1.87 per share, slightly above the expected $1.85, but revenue fell short at $21.87 billion compared to the anticipated $22.32 billion.

The CEO of Wells Fargo indicated that while consumer health appears strong, with delinquencies remaining low and primary checking accounts growing for 14 consecutive quarters, the bank's trading activities slowed sharply in late September.

Johnson & Johnson's earnings came in at $2.59 per share, beating expectations of $2.53, but the company flagged weakness in its Medtech segment due to geopolitical conflicts and pricing pressures in international markets.

Domino's reported better-than-expected earnings of $4.60 per share, surpassing the forecast of $4.36, but comparable store sales growth was only 3.1%, indicating slow growth at existing locations.

Our interpretation: The mixed earnings reports from Wells Fargo and Johnson & Johnson, coupled with slow growth at Domino's, suggest a cautious outlook for consumer spending and investment sentiment in the current economic environment.

JNJ / Reason

Johnson & Johnson's earnings and Medtech segment weakness are highlighted.

JNJ / Transmission

Johnson & Johnson's earnings beat expectations but flagged weakness in Medtech. This can affect JNJ through concerns about future growth and profitability.

15m—20m

Banks are funding a significant amount of private credit off balance sheet, which could pose risks, particularly for regional banks with notable exposure.

Dory Wiley expressed concerns regarding the potential impact of private credit on banks' balance sheets, emphasizing the need for ongoing monitoring.

Johnson & Johnson raised its profit forecast for the full year to $11.15, up from $11.11 last quarter, driven by strong pharmaceutical sales.

The CFO of Johnson & Johnson reported that prescriptions for their new psoriasis treatment, acotide, have doubled, indicating robust market demand.

Revenue from Johnson & Johnson's injection treatment for psoriasis, Trampaya, increased by 68%, reflecting growth in their pharmaceutical offerings.

Our interpretation: The increasing reliance on private credit by banks, coupled with strong performance in pharmaceutical sales, suggests a divergence in sector health that could influence investment strategies.

JNJ / Reason

Johnson & Johnson's profit forecast and product performance were directly discussed.

JNJ / Transmission

The CFO's report on increased prescriptions and revenue growth indicates strong demand for J&J's products. This can positively influence JNJ's stock price through improved investor sentiment and earnings expectations.

20m—25m

Johnson & Johnson has raised its profit forecast for the full year to $11.15 per share, up from $11.11 previously.

The company's new psoriasis drug, acotide, has seen a significant increase in prescriptions, doubling in the past quarter.

UnitedHealth Group reported Q3 results with revenue of $112.7 billion and an adjusted EPS of $4.69, exceeding expectations.

UnitedHealth's medical cost ratio came in lower than expected at 88.4%, which is beneficial for their financial performance.

Rising premiums for health insurance are a concern for consumers, as they may lead to increased costs reflected in the Consumer Price Index (CPI).

Our interpretation: The adjustments in healthcare costs, driven by rising premiums and the integration of AI in operations, could lead to increased scrutiny on insurers' balance sheets, potentially impacting their stock performance.

JNJ / Reason

Johnson & Johnson's profit forecast and new drug performance are directly discussed.

JNJ / Transmission

The company raised its profit forecast due to strong drug sales. This can positively impact JNJ's stock performance through improved investor sentiment.